<DOC>
	<DOCNO>NCT02344303</DOCNO>
	<brief_summary>Assess electrocardiogram effect TRV130 relative placebo therapeutic supratherapeutic dos .</brief_summary>
	<brief_title>Study Effects TRV130 , Therapeutic Supra Therapeutic Doses , QTc Intervals</brief_title>
	<detailed_description>- Part A study assess clinical safety data TRV130 - Part B study ass effect single dose TRV130 QTc</detailed_description>
	<mesh_term>Moxifloxacin</mesh_term>
	<criteria>Healthy male and/or female subject age 18 45 inclusive . Women must either ) postmenopausal ; b ) surgically sterile ; c ) childbearing potential practice contraception remain sexually inactive . Men must willing abstain sperm donation time Screening Followup Visit , sexually active woman childbearing potential , must protect acceptable form effective contraception Followup Visit . Past present disease include , limited , significant medical abnormality include : psychiatric , neurologic , pulmonary , cardiac , gastrointestinal , genitourinary , renal , metabolic , endocrinologic autoimmune disorder . Has previously participate another TRV130 clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>